Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics, Inc. (KYMR) is a clinical-stage biopharmaceutical company advancing targeted protein degradation therapies for immune-inflammatory diseases and oncology. This dedicated news hub provides investors and industry observers with timely updates on the company’s scientific progress, clinical developments, and strategic initiatives.
Access comprehensive coverage of KYMR’s innovative pipeline, including updates on STAT6 and IRAK4 degrader programs, partnership announcements, and financial disclosures. Our curated news collection enables efficient tracking of milestones in protein degradation research – from preclinical breakthroughs to clinical trial results – while maintaining strict adherence to factual reporting standards.
Key content categories include regulatory filings, peer-reviewed research highlights, executive leadership updates, and analysis of therapeutic platform advancements. All materials are sourced from verified channels to ensure reliability for investment research and sector analysis.
Bookmark this page for streamlined access to KYMR’s latest developments in transforming undruggable targets into viable treatment pathways through proprietary degradation technology. Check regularly for updates on oral small molecule therapies that aim to combine biologics-like efficacy with enhanced patient convenience.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company, has announced the pricing of a $250.8 million public offering of common stock and pre-funded warrants. The company is offering 5,044,500 shares at $44.00 per share and 655,500 pre-funded warrants at $43.9999 each.
The offering includes a 30-day option for underwriters to purchase up to 855,000 additional shares. The proceeds will support Kymera's pipeline of preclinical and clinical degrader programs. The offering is expected to close on June 30, 2025, with Morgan Stanley, J.P. Morgan, Jefferies, TD Cowen, and Leerink Partners acting as joint book-running managers.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company, has announced a proposed public offering of $250.0 million of common stock and pre-funded warrants. The company is also granting underwriters a 30-day option to purchase up to an additional $37.5 million of shares.
The proceeds will be used to advance Kymera's pipeline of preclinical and clinical degrader programs targeting immunological diseases. Morgan Stanley, J.P. Morgan, Jefferies, TD Cowen and Leerink Partners are serving as joint book-running managers for the offering.
Kymera Therapeutics (NASDAQ: KYMR) announced that Sanofi will advance KT-485, their next-generation oral IRAK4 degrader, into clinical testing while discontinuing development of KT-474. KT-485 demonstrated enhanced selectivity, potency, and favorable safety in preclinical testing.
Under their collaboration agreement, Kymera received a $20 million milestone payment in Q2 2025 and remains eligible for up to $975 million in potential milestones, plus double-digit royalties. Kymera maintains the option for a 50/50 development and profit share of KT-485 in the U.S.
Gilead Sciences (NASDAQ: GILD) and Kymera Therapeutics (NASDAQ: KYMR) have entered into an exclusive option and license agreement to develop novel oral molecular glue CDK2 degraders for cancer treatment. The collaboration focuses on developing a new type of drug designed to remove CDK2, a key protein in tumor growth, rather than just inhibiting it.
Under the agreement, Kymera could receive up to $750 million in total payments, including $85 million in upfront and potential option exercise payments, plus tiered royalties ranging from high single-digit to mid-teens on net sales. Kymera will lead research activities, while Gilead will gain global rights upon exercising its option. The deal is expected to impact Gilead's 2025 EPS by approximately $0.02-$0.03.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, has announced its participation in three major investor conferences in June 2025:
- Jefferies Global Healthcare Conference in New York on June 5 at 8:10 a.m. ET
- Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 10 at 3:20 p.m. ET
- Wolfe Research Virtual Biotech Day on June 26 (one-on-one meetings only)
Live webcasts of the presentations will be available on Kymera's website under the Investors section, with replays archived for later viewing.
- Achieved >90% degradation across multiple species with low oral doses
- Demonstrated superior efficacy to current standards in lupus and RA models
- Showed favorable safety profile up to 200-fold projected human efficacious levels
- Effectively blocked multiple inflammatory pathways in patient samples